Trials / Completed
CompletedNCT00610428
Staccato Prochlorperazine in Migraine (in Clinic)
A Multi-center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of StaccatoTM Prochlorperazine for Inhalation in Patients With Migraine Headache
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Alexza Pharmaceuticals, Inc. · Unknown
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Development of Staccato Prochlorperazine for the treatment of migraine headache.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Staccato Placebo | Inhaled Staccato Placebo |
| DRUG | Staccato Prochlorperazine 5 mg | Inhaled Prochlorperazine 5 mg |
| DRUG | Staccato Prochlorperazine 10 mg | Inhaled Prochlorperazine10 mg |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2005-10-01
- Completion
- 2005-10-01
- First posted
- 2008-02-08
- Last updated
- 2018-01-25
- Results posted
- 2018-01-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00610428. Inclusion in this directory is not an endorsement.